Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Yang Yang; Chenguang Shen; Jinxiu Li; Jing Yuan; Jinli Wei; Fengmin Huang; Fuxiang Wang; Guobao Li; Yanjie Li; Li Xing; Ling Peng; Minghui Yang; Mengli Cao; Haixia Zheng; Weibo Wu; Rongrong Zou; Delin Li; Zhixiang Xu; Haiyan Wang; Mingxia Zhang; Zheng Zhang; George F. Gao; Chengyu Jiang; Lei Liu; Yingxia Liu

doi:10.1016/j.jaci.2020.04.027

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Yang Yang
, Chenguang Shen
, Jinxiu Li
, Jing Yuan
, Jinli Wei
, Fengmin Huang
, Fuxiang Wang
, Guobao Li
, Yanjie Li
, Li Xing
, Ling Peng
, Minghui Yang
, Mengli Cao
, Haixia Zheng
, Weibo Wu
, Rongrong Zou
, Delin Li
, Zhixiang Xu
, Haiyan Wang
, Mingxia Zhang

Zheng Zhang, George F. Gao, Chengyu Jiang^*, Lei Liu^*, Yingxia Liu

^*Corresponding author for this work

Second Hospital Affiliated to Southern University of Science and Technology
Chinese Academy of Medical Sciences
CAS - Institute of Microbiology

Research output: Contribution to journal › Article › peer-review

549 Citations (Scopus)

Abstract

Background: The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 was first reported in Wuhan, December 2019, and continuously poses a serious threat to public health, highlighting the urgent need of identifying biomarkers for disease severity and progression. Objective: We sought to identify biomarkers for disease severity and progression of COVID-19. Methods: Forty-eight cytokines in the plasma samples from 50 COVID-19 cases including 11 critically ill, 25 severe, and 14 moderate patients were measured and analyzed in combination with clinical data. Results: Levels of 14 cytokines were found to be significantly elevated in COVID-19 cases and showed different expression profiles in patients with different disease severity. Moreover, expression levels of IFN-γ–induced protein 10, monocyte chemotactic protein-3, hepatocyte growth factor, monokine-induced gamma IFN, and macrophage inflammatory protein 1 alpha, which were shown to be highly associated with disease severity during disease progression, were remarkably higher in critically ill patients, followed by severe and then the moderate patients. Serial detection of the 5 cytokines in 16 cases showed that continuously high levels were associated with deteriorated progression of disease and fatal outcome. Furthermore, IFN-γ–induced protein 10 and monocyte chemotactic protein-3 were excellent predictors for the progression of COVID-19, and the combination of the 2 cytokines showed the biggest area under the curve of the receiver-operating characteristics calculations with a value of 0.99. Conclusions: In this study, we report biomarkers that are highly associated with disease severity and progression of COVID-19. These findings add to our understanding of the immunopathologic mechanisms of severe acute respiratory syndrome coronavirus 2 infection, and provide potential therapeutic targets and strategies.

Original language	English
Pages (from-to)	119-127.e4
Journal	Journal of Allergy and Clinical Immunology
Volume	146
Issue number	1
DOIs	https://doi.org/10.1016/j.jaci.2020.04.027
Publication status	Published - Jul 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
SARS-CoV-2
biomarkers
disease progression
prediction

Access to Document

10.1016/j.jaci.2020.04.027

Cite this

Yang, Y., Shen, C., Li, J., Yuan, J., Wei, J., Huang, F., Wang, F., Li, G., Li, Y., Xing, L., Peng, L., Yang, M., Cao, M., Zheng, H., Wu, W., Zou, R., Li, D., Xu, Z., Wang, H., ... Liu, Y. (2020). Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. Journal of Allergy and Clinical Immunology, 146(1), 119-127.e4. https://doi.org/10.1016/j.jaci.2020.04.027

@article{8b665b35ae9b42449d1c5d28eedbf95a,

title = "Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19",

abstract = "Background: The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 was first reported in Wuhan, December 2019, and continuously poses a serious threat to public health, highlighting the urgent need of identifying biomarkers for disease severity and progression. Objective: We sought to identify biomarkers for disease severity and progression of COVID-19. Methods: Forty-eight cytokines in the plasma samples from 50 COVID-19 cases including 11 critically ill, 25 severe, and 14 moderate patients were measured and analyzed in combination with clinical data. Results: Levels of 14 cytokines were found to be significantly elevated in COVID-19 cases and showed different expression profiles in patients with different disease severity. Moreover, expression levels of IFN-γ–induced protein 10, monocyte chemotactic protein-3, hepatocyte growth factor, monokine-induced gamma IFN, and macrophage inflammatory protein 1 alpha, which were shown to be highly associated with disease severity during disease progression, were remarkably higher in critically ill patients, followed by severe and then the moderate patients. Serial detection of the 5 cytokines in 16 cases showed that continuously high levels were associated with deteriorated progression of disease and fatal outcome. Furthermore, IFN-γ–induced protein 10 and monocyte chemotactic protein-3 were excellent predictors for the progression of COVID-19, and the combination of the 2 cytokines showed the biggest area under the curve of the receiver-operating characteristics calculations with a value of 0.99. Conclusions: In this study, we report biomarkers that are highly associated with disease severity and progression of COVID-19. These findings add to our understanding of the immunopathologic mechanisms of severe acute respiratory syndrome coronavirus 2 infection, and provide potential therapeutic targets and strategies.",

keywords = "COVID-19, SARS-CoV-2, biomarkers, disease progression, prediction",

author = "Yang Yang and Chenguang Shen and Jinxiu Li and Jing Yuan and Jinli Wei and Fengmin Huang and Fuxiang Wang and Guobao Li and Yanjie Li and Li Xing and Ling Peng and Minghui Yang and Mengli Cao and Haixia Zheng and Weibo Wu and Rongrong Zou and Delin Li and Zhixiang Xu and Haiyan Wang and Mingxia Zhang and Zheng Zhang and Gao, \{George F.\} and Chengyu Jiang and Lei Liu and Yingxia Liu",

note = "Publisher Copyright: {\textcopyright} 2020 American Academy of Allergy, Asthma \& Immunology",

year = "2020",

month = jul,

doi = "10.1016/j.jaci.2020.04.027",

language = "English",

volume = "146",

pages = "119--127.e4",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Elsevier Inc.",

number = "1",

}

Yang, Y, Shen, C, Li, J, Yuan, J, Wei, J, Huang, F, Wang, F, Li, G, Li, Y, Xing, L, Peng, L, Yang, M, Cao, M, Zheng, H, Wu, W, Zou, R, Li, D, Xu, Z, Wang, H, Zhang, M, Zhang, Z, Gao, GF, Jiang, C, Liu, L & Liu, Y 2020, 'Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19', Journal of Allergy and Clinical Immunology, vol. 146, no. 1, pp. 119-127.e4. https://doi.org/10.1016/j.jaci.2020.04.027

TY - JOUR

T1 - Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

AU - Yang, Yang

AU - Shen, Chenguang

AU - Li, Jinxiu

AU - Yuan, Jing

AU - Wei, Jinli

AU - Huang, Fengmin

AU - Wang, Fuxiang

AU - Li, Guobao

AU - Li, Yanjie

AU - Xing, Li

AU - Peng, Ling

AU - Yang, Minghui

AU - Cao, Mengli

AU - Zheng, Haixia

AU - Wu, Weibo

AU - Zou, Rongrong

AU - Li, Delin

AU - Xu, Zhixiang

AU - Wang, Haiyan

AU - Zhang, Mingxia

AU - Zhang, Zheng

AU - Gao, George F.

AU - Jiang, Chengyu

AU - Liu, Lei

AU - Liu, Yingxia

PY - 2020/7

Y1 - 2020/7

N2 - Background: The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 was first reported in Wuhan, December 2019, and continuously poses a serious threat to public health, highlighting the urgent need of identifying biomarkers for disease severity and progression. Objective: We sought to identify biomarkers for disease severity and progression of COVID-19. Methods: Forty-eight cytokines in the plasma samples from 50 COVID-19 cases including 11 critically ill, 25 severe, and 14 moderate patients were measured and analyzed in combination with clinical data. Results: Levels of 14 cytokines were found to be significantly elevated in COVID-19 cases and showed different expression profiles in patients with different disease severity. Moreover, expression levels of IFN-γ–induced protein 10, monocyte chemotactic protein-3, hepatocyte growth factor, monokine-induced gamma IFN, and macrophage inflammatory protein 1 alpha, which were shown to be highly associated with disease severity during disease progression, were remarkably higher in critically ill patients, followed by severe and then the moderate patients. Serial detection of the 5 cytokines in 16 cases showed that continuously high levels were associated with deteriorated progression of disease and fatal outcome. Furthermore, IFN-γ–induced protein 10 and monocyte chemotactic protein-3 were excellent predictors for the progression of COVID-19, and the combination of the 2 cytokines showed the biggest area under the curve of the receiver-operating characteristics calculations with a value of 0.99. Conclusions: In this study, we report biomarkers that are highly associated with disease severity and progression of COVID-19. These findings add to our understanding of the immunopathologic mechanisms of severe acute respiratory syndrome coronavirus 2 infection, and provide potential therapeutic targets and strategies.

AB - Background: The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 was first reported in Wuhan, December 2019, and continuously poses a serious threat to public health, highlighting the urgent need of identifying biomarkers for disease severity and progression. Objective: We sought to identify biomarkers for disease severity and progression of COVID-19. Methods: Forty-eight cytokines in the plasma samples from 50 COVID-19 cases including 11 critically ill, 25 severe, and 14 moderate patients were measured and analyzed in combination with clinical data. Results: Levels of 14 cytokines were found to be significantly elevated in COVID-19 cases and showed different expression profiles in patients with different disease severity. Moreover, expression levels of IFN-γ–induced protein 10, monocyte chemotactic protein-3, hepatocyte growth factor, monokine-induced gamma IFN, and macrophage inflammatory protein 1 alpha, which were shown to be highly associated with disease severity during disease progression, were remarkably higher in critically ill patients, followed by severe and then the moderate patients. Serial detection of the 5 cytokines in 16 cases showed that continuously high levels were associated with deteriorated progression of disease and fatal outcome. Furthermore, IFN-γ–induced protein 10 and monocyte chemotactic protein-3 were excellent predictors for the progression of COVID-19, and the combination of the 2 cytokines showed the biggest area under the curve of the receiver-operating characteristics calculations with a value of 0.99. Conclusions: In this study, we report biomarkers that are highly associated with disease severity and progression of COVID-19. These findings add to our understanding of the immunopathologic mechanisms of severe acute respiratory syndrome coronavirus 2 infection, and provide potential therapeutic targets and strategies.

KW - COVID-19

KW - SARS-CoV-2

KW - biomarkers

KW - disease progression

KW - prediction

UR - https://www.scopus.com/pages/publications/85084729783

U2 - 10.1016/j.jaci.2020.04.027

DO - 10.1016/j.jaci.2020.04.027

M3 - Article

C2 - 32360286

AN - SCOPUS:85084729783

SN - 0091-6749

VL - 146

SP - 119-127.e4

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 1

ER -

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this